F-1/A: ANEW Health Seeks Waiver for IPO, Plans Nasdaq Listing Under 'AVG' Symbol

ANEW Health Limited, a Cayman Islands-based company, is requesting a waiver from the SEC regarding audited financial statement requirements for its proposed IPO and Nasdaq listing.

Summary

• ANEW Health Limited, a foreign private issuer from the Cayman Islands, is seeking a waiver from the SEC regarding the 12-month requirement for audited financial statements in its Form F-1 registration statement for a proposed IPO.
• The company represents that it is not required to comply with this requirement in any other jurisdiction and that compliance is impracticable and involves undue hardship.
• ANEW Health anticipates its audited financial statements for the fiscal year ended March 31, 2024, will be available in late June 2025.
• The company assures that it will not seek effectiveness of the Registration Statement if its audited financial statements are older than 15 months at the time of the IPO.
• The company is planning to list its Ordinary Shares on the Nasdaq Global Market under the symbol 'AVG'.
• The initial public offering price (the Offering Price) will be US$4.00 per Ordinary Shares.
• The company is offering 5,000,000 ordinary shares.
• The company has granted the underwriters an option to purchase up to 750,000 additional Ordinary Shares from us at the initial public offering price, less underwriting discounts, within 45 days from the closing of this Offering to cover over-allotments, if any.

Sentiment

Score: 6

Explanation: The document is primarily procedural, focusing on a waiver request and registration details. While the IPO plan is positive, the delay in financial statement availability and associated risks temper the overall sentiment.

Positives

• The company is not currently a public reporting company in any jurisdiction.
• The company is not required by any jurisdiction outside the United States to prepare consolidated financial statements audited under any generally accepted auditing standards for any interim period.

Negatives

• Full compliance with Item 8.A.4 of Form 20-F at present is impracticable and involves undue hardship for the Company.
• The company does not anticipate that its audited financial statements for the fiscal year ended March 31, 2024 will be available until late June, 2025.

Risks

• There is no assurance that the application to list on the Nasdaq Global Market will be approved, and if the application is not approved by Nasdaq, this Offering cannot be completed.
• Investing in the Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment.
• The PRC government may exercise significant direct oversight and discretion over the conduct of the business and may intervene or influence operations, which could result in a material change in operations and/or the value of the Ordinary Shares.
• The delisting of Ordinary Shares, or the threat of their being delisted, may materially and adversely affect the value of your investment.

Future Outlook

The company does not anticipate that its audited financial statements for the fiscal year ended March 31, 2024 will be available until late June, 2025, but assures that it will not seek effectiveness of the Registration Statement if its audited financial statements are older than 15 months at the time of the IPO.

Management Comments

• The company represents to the Commission that it is not required by any jurisdiction outside the United States to prepare consolidated financial statements audited under any generally accepted auditing standards for any interim period.
• The company represents to the Commission that full compliance with Item 8.A.4 of Form 20-F at present is impracticable and involves undue hardship for the Company.

Industry Context

This announcement reflects a company navigating regulatory requirements while pursuing a public listing, a common scenario in the current market environment, particularly for companies with international operations.

Stakeholder Impact

• Potential investors should be aware of the risks associated with investing in a foreign private issuer and the potential for price volatility.
• Existing shareholders may experience dilution upon the issuance of new shares.

Next Steps

• The company needs to obtain a waiver from the SEC.
• The company needs to complete the audit of its financial statements for the fiscal year ended March 31, 2024.
• The company needs to secure approval for listing on the Nasdaq Global Market.
• The company needs to close the IPO.

Key Dates

Keywords

IPO, initial public offering, ANEW Health Limited, waiver request, SEC, Nasdaq, financial statements, listing